Verastem, Inc. (VSTM)
NASDAQ: VSTM · Real-Time Price · USD
7.29
+0.12 (1.67%)
At close: May 12, 2025, 4:00 PM
7.20
-0.09 (-1.24%)
After-hours: May 12, 2025, 7:11 PM EDT
Verastem Employees
Verastem had 78 employees as of December 31, 2024. The number of employees increased by 5 or 6.85% compared to the previous year.
Employees
78
Change (1Y)
5
Growth (1Y)
6.85%
Revenue / Employee
$128,205
Profits / Employee
-$1,674,833
Market Cap
375.36M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
VSTM News
- 4 days ago - FDA Approves the AVMAPKI™ FAKZYNJA™ Combination Therapy as the First-Ever Treatment for Adult Patients with KRAS-mutated Recurrent Low-Grade Serous Ovarian Cancer - Business Wire
- 4 days ago - U.S. FDA approves Verastem's cancer therapy - Reuters
- 11 days ago - Verastem Oncology to Present at Upcoming Investor Conferences - Business Wire
- 17 days ago - Verastem Oncology Announces $75 million Private Placement - Business Wire
- 19 days ago - Verastem Oncology Announces U.S. IND Clearance of VS-7375, Oral KRAS G12D (ON/OFF) Inhibitor, Enabling Phase 1/2a Trial in Advanced Solid Tumors - Business Wire
- 4 weeks ago - Verastem: RAMP-203 Study Could Be Next Big Win For Avutometinib Combination - Seeking Alpha
- 5 weeks ago - Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 6 weeks ago - Verastem Oncology Announces Multiple Presentations Focused on RAS/MAPK Pathway Inhibition at AACR Annual Meeting 2025 - Business Wire